Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.Zacks Premium also includes the Zacks Style Scores.What are the Zacks Style Scores?Developed ...

Dexcom, Inc. (NASDAQ:DXCM) Q3 2023 Earnings Conference Call October 26, 2023 4:30 PM ET Company Participants Sean Christensen - Director, Corporate Affairs & Head of IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sylvain - EVP, CFO & CAO Jake Leach - EVP, Chief Operating Officer Terry Lauver - Chief Commercial Officer Conference Call Participants Robert Marcus - JPMorgan Chase & Co. Margaret Kaczor - William Blair & Company Larry Biegelsen - Wells Fargo Securities Danielle Antalffy - UBS Matt T ...

• • • • Three Months Ended September 30, Three Months Ended September 30, (In millions) 2023 2022 (In millions, except per share data) 2023 2022 GAAP gross profit $ 623.3 $ 494.2 GAAP net income $ 120.7 $ 101.2 Amortization of intangible assets (1) 7.1 — Amortization of intangible assets (1) 8.8 1.8 Non-GAAP gross profit $ 630.4 $ 494.2 Business transition and related costs (2) 1.1 1.6 Intellectual property litigation costs (3) 23.5 9.9 GAAP operating income $ 205.5 $ 147.5 Income from equity investments (4 ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DEXCOM, INC. (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisdiction of incorporat ...

Financial Data and Key Metrics Changes - The company reported worldwide revenue of $871 million for Q2 2023, a 26% increase compared to $696 million in Q2 2022 [17] - U.S. revenue totaled $617 million, up 21% from $511 million in the same quarter last year [17] - International revenue grew 38% to $255 million, with organic revenue growth of 40% [18] - Gross profit was $553.5 million, representing 63.5% of revenue, down from 64.6% in Q2 2022 [20] - Operating income was $158.4 million, or 18.2% of revenue, compared to $101.9 million or 14.6% in the same quarter last year [22] - Net income for Q2 was $139.4 million, or $0.34 per share, with cash and cash equivalents exceeding $3.6 billion [22] Business Line Data and Key Metrics Changes - The G7 product launch has attracted a significant number of new users, with 8,000 new physicians prescribing G7 in the U.S. [8][9] - The majority of G7 users are new to Dexcom, indicating successful market penetration [8] - The company has seen a notable uptick in demand in the Medicare business, marking Q2 as the highest new patient quarter in its history [12] Market Data and Key Metrics Changes - The company expanded its international G7 launch into six new markets, including Canada and Argentina [13] - The U.K. has shown significant growth due to broadened reimbursement and new clinical recommendations [19] - The company has established over 60% commercial coverage for basal insulin users, validating its value proposition [11] Company Strategy and Development Direction - The company aims to broaden access to its products and has successfully expanded reimbursement coverage for G7 [9][10] - A new product specifically for non-insulin users is expected to launch early next year, leveraging G7 hardware with tailored software [15][76] - The company is focused on operational efficiency and cost management, generating over 450 basis points of operating expense leverage [21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's growth trajectory, citing strong demand and successful product launches [7][25] - The company raised its full-year revenue guidance to a range of $3.50 billion to $3.55 billion, reflecting a strong start to the year [23] - Management noted that the initial response from the clinical community regarding basal insulin coverage has been encouraging [12] Other Important Information - The company has begun commercial production at its Malaysia facility, which is expected to become its largest operation [22] - The company is actively working on reimbursement for its products and has seen rapid progress in this area [9] Q&A Session Summary Question: What drove the international growth this quarter? - Management attributed international growth to increased access, the successful G7 launch in 13 countries, and the Dexcom ONE portfolio strategy [30][31] Question: What is the source of confidence behind the raised guidance? - The raised guidance is based on strong performance outside the U.S. and successful coverage wins domestically, particularly with the G7 launch [34] Question: How much of the sequential improvement in U.S. revenue was from basal? - Management indicated that while basal contributed nominally in Q2, the majority of growth was driven by taking share in existing markets [40] Question: Is there any concern regarding the guidance for the second half of the year? - Management expressed no concerns about the back half of the year, emphasizing confidence in the raised guidance and record patient growth [44] Question: Can you quantify the contribution of Dexcom ONE to international growth? - Management did not provide specific numbers but indicated that Dexcom ONE is contributing positively to growth in newly launched markets [48][50] Question: How is the competitive environment changing? - Management noted that they are gaining share across major reimbursed geographies and that G7 has been well received, with strong pricing trends [60]

• • • • Three Months Ended June 30, Three Months Ended June 30, (In millions) 2023 2022 (In millions, except per share data) 2023 2022 GAAP gross profit $ 546.4 $ 449.5 GAAP net income $ 115.9 $ 50.9 Amortization of intangible assets (1) 7.1 — Amortization of intangible assets (1) 8.8 1.9 Non-GAAP gross profit $ 553.5 $ 449.5 Business transition and related costs (2) 0.7 13.8 Intellectual property litigation costs (3) 20.8 9.2 GAAP operating income $ 128.1 $ 77.0 Adjustments related to taxes (4) (6.8) (6.3) ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DEXCOM, INC. (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisdiction of incorporation o ...

Dexcom, Inc. (NASDAQ:DXCM) Q1 2023 Earnings Conference Call April 27, 2023 4:30 PM ET Company Participants Sean Christensen - Director, Corporate Affairs & Head of IR Kevin Sayer - Executive Chairman, CEO & President Jereme Sylvain - EVP, CFO & CAO Conference Call Participants Robert Marcus - JPMorgan Chase & Co. Jeffrey Johnson - Robert W. Baird & Co. Lawrence Biegelsen - Wells Fargo Securities Cecilia Furlong - Morgan Stanley Danielle Antalffy - UBS Mathew Blackman - Stifel, Nicolaus & Company Margaret Ka ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 000-51222 DEXCOM, INC. (Exact name of registrant as specified in its charter) Delaware 33-0857544 (State or other jurisdiction of incorporation ...

Financial Data and Key Metrics Changes - For Q4 2022, the company reported worldwide revenue of $815 million, a 20% increase from $698 million in Q4 2021, with U.S. revenue growing 17% to $606 million from $517 million [15][16] - International revenue grew 15% to $209 million, with organic revenue growth of 27% in Q4 [17] - Operating income was $172.1 million, representing 21.1% of revenue, compared to $12 million or 1.7% in Q4 2021 [19] - Adjusted EBITDA for Q4 was $237.1 million, or 29.1% of revenue, compared to $67.3 million or 9.6% in Q4 2021 [19] - The company closed the quarter with approximately $2.5 billion in cash and cash equivalents, providing flexibility for growth opportunities [19] Business Line Data and Key Metrics Changes - The company added nearly 450,000 new users in 2022, ending the year with close to 1.7 million customers globally [6] - The G7 product received positive feedback, with 97% of initial users finding it easy to use, and production capacity ramped up to over 100,000 sensors per day [11][12] Market Data and Key Metrics Changes - The proposed Medicare coverage expansion could nearly double the addressable reimbursed market in the U.S. for the basal-only type 2 diabetes population, estimated at 3 million people [9] - International access initiatives expanded reimbursed coverage by 3.5 million lives over the past 18 months [10] Company Strategy and Development Direction - The company aims to build a foundation for sustainable growth through new product launches, market development, and enhancing connectivity [8] - The G7 product launch is seen as a pivotal moment, with plans to increase awareness through marketing efforts, including a Super Bowl commercial [13][35] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the G7 launch and its potential impact on growth, with expectations for total revenue in 2023 to be between $3.35 billion and $3.49 billion, reflecting a growth rate of 15% to 20% [20] - The company anticipates a temporary decline in gross profit margin due to the G7 launch but expects to return to long-term targets as production scales [22][43] Other Important Information - The company emphasized the importance of driving awareness among physicians and patients regarding Medicare coverage decisions [49] - The company plans to invest significantly in commercial infrastructure and marketing to support the G7 launch and international expansion [58][59] Q&A Session All Questions and Answers Question: What percentage of covered lives are currently in the commercial channel for G7 and expectations for the next quarter? - Management indicated that they are ahead of schedule with pharmacy contracts, reducing expected impacts from the bridge program [26] Question: What is the expected growth contribution from the type 2 basal population in 2023? - Management conservatively estimates a 1% contribution, with potential for higher exit velocity as coverage expands [30][31] Question: How is the adoption pace for type 2 basal expected to evolve over the next 18-24 months? - Management noted that awareness and marketing efforts will be crucial for driving adoption in this segment [33] Question: What is the feedback on G7 in European markets and its impact on share against competitors? - Initial responses to G7 have been positive, with growth driven by established products and new coverage [39][40] Question: How will gross margins ramp throughout 2023? - Management expects lower margins in the first half due to the G7 launch but anticipates improvement as production scales [42][43] Question: What is the expected impact of the bridging program on revenue and gross margins? - The bridging program is trending better than expected, which may positively influence revenue and margins [46] Question: How aware are physicians and patients of the Medicare decision, and what is the plan to drive awareness? - Management acknowledged the need to actively promote awareness among both physicians and patients [49] Question: What are the expectations for U.S. growth in the first quarter and the impact of the Super Bowl ad? - Management expects continued strong new patient growth, with the Super Bowl ad anticipated to drive significant interest [50][53] Question: What are the sources of operating expense growth in 2023? - The largest increases will be in commercial spending to support G7 and international expansion [56][58] Question: How does the company view the long-term gross margin outlook with G7? - Management remains committed to a long-term gross margin target of 65%, with potential for improvement as production efficiencies are realized [62][63]